Floatz logo

Memantine Hydrochloride

Neuroendocrine Prostate Cancer (NEPC)

Bin XuPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Neuroendocrine Prostate Cancer (NEPC) cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Tarlatamab
Inkeun Park
Phase 2B
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Ipilimumab
Andrew J. Armstrong, MD
Phase 2CCC

View all 35 →

Same molecule, other indications

Memantine Hydrochloride is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
67 / 100
View asset →
frontotemporal dementiaDormant
B
Indicative ·
62 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →